Patent 11607395 was granted and assigned to CuraSen Therapeutics on March, 2023 by the United States Patent and Trademark Office.
In various aspects and embodiments provided are compositions and methods for identifying patients in need of improving cognition and/or treating a neurodegenerative disease in a patient and treating such patient. More specifically, the disclosure in some embodiments includes administration of a β-AR agonist and a peripherally acting β-blocker (PABRA) to a patient in need thereof.